3
Participants
Start Date
November 4, 2014
Primary Completion Date
January 11, 2022
Study Completion Date
January 11, 2022
Treatment Based on Genetic Mutation
Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
Treatment Based on No Genetic Mutation
Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
University of Texas MD Anderson Cancer Center, Houston
Cancer Institute Gustave Roussy, Villejuif
Chaim Sheba Medical Center at Tel Hasomer, Ramat Gan
Vall D'Hebron University Hospital, Barcelona
European Commission
OTHER
M.D. Anderson Cancer Center
OTHER